Pallavi Tawde, PhD
Vice President, Antibody Therapeutics
Dr. Tawde has served as Novasenta’s Vice President of Antibody Therapeutics since May 2022. Throughout her career at Global BioPharma’s and Biotech startups, she has implemented disruptive technology platforms for therapeutic antibody discovery & development from single B cells, hybridoma, and display technologies. She has worked on a wide spectrum of disease areas and targets encompassing – Immuno-Oncology, Neurodegenerative diseases, Autoimmune, Infectious diseases, and Allergy with focus on target identification, lead antibody generation & development. Her expansive industry experience spans the discovery & preclinical development of therapeutic antibodies, leading to IND-enabling preclinical studies and advancement to FDA filings.
She started her BioPharma career at Pfizer where she led efforts to evaluate a broad range of technologies, build partnerships, perform scientific and IP due diligence, contributing towards in-licensing for antibody therapeutics against infectious and autoimmune diseases. After her tenure at Pfizer, Dr. Tawde was appointed at Bristol Myers Squibb to lead the pioneering efforts of building state-of-the-art Single B cell, Ab-NGS and Display Technology platforms for Antibody Discovery. At BMS, she was recognized for scientific innovation and excellence towards biotherapeutic portfolio development focusing on Immuno-Oncology. Subsequently, advancing into a Senior leadership role at Denali Therapeutics, she headed Antibody Discovery, directing large molecule pipeline generation for neurodegenerative diseases. Prior to Novasenta, Dr. Tawde served as a Senior Director, Antibody Therapeutics at TrueBinding, a clinical stage biotech focused on Neurodegeneration, Fibrosis and Oncology. She oversaw discovery, engineering, and early development of a portfolio of new molecular entities in the pursuit of both cutting-edge science and breakthrough antibody therapeutics.
Dr. Tawde earned her Bachelor’s and Master’s degree in Microbiology & Immunology from the University of Mumbai, India, and Ph.D. in Cell and Molecular Immunology from Florida State University. She completed her postdoctoral fellowship at Seattle Biomed (CIDR funded by the Gates Foundation) contributing to HIV Vaccines.